Market Overview

UPDATE: Citigroup Initiates Supernus Pharmaceuticals at Neutral; Fully Valued

Supernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label
A Look Into Supernus Pharma's Investor Day

Citigroup initiated coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Neutral/High Risk rating and a $14 price target.

Citigroup noted, "We recognize the potential opportunities for SUPN's extended release epilepsy drugs Oxtellar XR (SPN-804) and Trokendi XR (Extended release Topamax). However believe the company is currently fairly valued based on the risk associated with the company's commercial execution to recognize the potential value of these programs. Physician feedback has highlighted the importance of impact of early launch efforts/impact on long-term potential for an epilepsy product."

Supernus Pharmaceuticals closed at $11.39 on Monday.

Latest Ratings for SUPN

Oct 2015Northland SecuritiesInitiates Coverage onOutperform
Jun 2015JefferiesUpgradesHoldBuy
Jun 2015Piper JaffrayMaintainsOverweight

View More Analyst Ratings for SUPN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (SUPN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters